658 related articles for article (PubMed ID: 10353302)
21. Fluticasone propionate compared with theophylline for mild-to-moderate asthma.
Galant SP; Lawrence M; Meltzer EO; Tomasko M; Baker KA; Kellerman DJ
Ann Allergy Asthma Immunol; 1996 Aug; 77(2):112-8. PubMed ID: 8760776
[TBL] [Abstract][Full Text] [Related]
22. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD007694. PubMed ID: 20091646
[TBL] [Abstract][Full Text] [Related]
23. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma.
Holliday SM; Faulds D; Sorkin EM
Drugs; 1994 Feb; 47(2):318-31. PubMed ID: 7512904
[TBL] [Abstract][Full Text] [Related]
24. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.
van Noord JA; Schreurs AJ; Mol SJ; Mulder PG
Thorax; 1999 Mar; 54(3):207-12. PubMed ID: 10325895
[TBL] [Abstract][Full Text] [Related]
25. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K
J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler.
Lundback B; Alexander M; Day J; Hebert J; Holzer R; Van Uffelen R; Kesten S; Jones AL
Respir Med; 1993 Nov; 87(8):609-20. PubMed ID: 8290745
[TBL] [Abstract][Full Text] [Related]
27. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
28. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists.
Creticos PS
Drugs; 2003; 63 Suppl 2():1-20. PubMed ID: 14984077
[TBL] [Abstract][Full Text] [Related]
29. Montelukast: a review of its therapeutic potential in persistent asthma.
Jarvis B; Markham A
Drugs; 2000 Apr; 59(4):891-928. PubMed ID: 10804041
[TBL] [Abstract][Full Text] [Related]
30. Inhaled corticosteroids in children with persistent asthma: effects on growth.
Zhang L; Prietsch SO; Ducharme FM
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009471. PubMed ID: 25030198
[TBL] [Abstract][Full Text] [Related]
31. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.
Nathan RA; Bleecker ER; Kalberg C;
Am J Med; 2001 Aug; 111(3):195-202. PubMed ID: 11530030
[TBL] [Abstract][Full Text] [Related]
32. Salmeterol/fluticasone propionate: a review of its use in asthma.
McKeage K; Keam SJ
Drugs; 2009; 69(13):1799-828. PubMed ID: 19719334
[TBL] [Abstract][Full Text] [Related]
33. Fluticasone furoate/vilanterol: a review of its use in patients with asthma.
Syed YY
Drugs; 2015 Mar; 75(4):407-18. PubMed ID: 25648266
[TBL] [Abstract][Full Text] [Related]
34. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.
Lipworth BJ
Arch Intern Med; 1999 May; 159(9):941-55. PubMed ID: 10326936
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma.
Sheikh S; Goldsmith LJ; Howell L; Eid N
Ann Allergy Asthma Immunol; 1999 Oct; 83(4):300-4. PubMed ID: 10541421
[TBL] [Abstract][Full Text] [Related]
36. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
37. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
38. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
Menendez R; Stanford RH; Edwards L; Kalberg C; Rickard K
Pharmacoeconomics; 2001; 19(8):865-74. PubMed ID: 11596838
[TBL] [Abstract][Full Text] [Related]
39. [Fluticasone propionate in children and infants with asthma].
Marchac V; Foussier V; Devillier P; Le Bourgeois M; Polak M
Arch Pediatr; 2007 Apr; 14(4):376-87. PubMed ID: 17289359
[TBL] [Abstract][Full Text] [Related]
40. Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma.
Jenkins C; Woolcock AJ; Saarelainen P; Lundback B; James MH
Respir Med; 2000 Jul; 94(7):715-23. PubMed ID: 10926345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
